ViAn Therapeutics
Topical antiangiogenic peptide for retinal vascular diseases
ViAn Therapeutics is a company in therapeutics based in United States, founded in 2023.
Profile
ViAn Therapeutics has developed c4551: an unprecedented antiangiogenic small cyclic peptide in a daily eyedrop for retinal diseases such as diabetic retinopathy and age-related macular degeneration. The company stems from three decades of pioneering research in a prominent angiogenesis and ophthalmology lab at the National University of Mexico. Napoleon Ferrara, a leader in the field of angiogenesis, credited for the discovery of VEG-F, is an advisor to the company. ViAn Therapeutics’ at-home daily eyedrop will disrupt existing modalities involving invasive and costly antibodies and small molecules.
Within the therapeutics space, the company focuses on its core offering rather than a broad product line.
United States is where the company is located.
It is recorded at the SOSV portfolio company stage.
Recorded headcount: 1 employees.
Public records show total funding of about $575K.
| Sector | Therapeutics |
|---|---|
| Country | United States |
| Founded | 2023 |
| Employees | 1 |
| Stage | SOSV portfolio company |
| Total funding | $575,000 |
Website: www.viantx.com
Create a free account